The New Horizons for Seniors Program (NHSP) is currently accepting funding applications of up to a maximum of $25,000 per year per organization for community-based projects. Your organization can submit multiple applications but the total of all applications combined must not exceed $25,000, including applicable taxes per year, per organization.

If you do not apply for a $25,000 grant, you can apply for a small grant of a maximum of $5,000 if you have not been funded for community-based projects for the last five years (since the 2012-2013 NHSP Call for proposals).

You can also be eligible to apply for a contribution of a maximum of $750,000 for pan-Canadian projects for up to three years, when a call for proposals is open.

The New Horizons for Seniors Program provides federal grants and contributions funding to organizations that want to help seniors (aged 55 and older) make a difference in the lives of others and in their communities.

This program provides funding for:

• projects that encourage seniors to play an important role in their communities by volunteering, participating in and leading community activities
• organizations to make necessary modifications or repairs to their existing facilities, or to purchase/replace equipment and furnishings to enable programs and activities for seniors

The FY18 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to explore the causative links between traumatic brain injury (TBI) and epilepsy, with the hope that, one day, post-traumatic epilepsy (PTE) will be preventable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY18 ERP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications should also address at least one of the ERP FY18 Focus Areas.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

The ERP FY18 Focus Areas are as follows:

Epidemiology:  Epidemiological characterization of PTE following TBI, which may include:

• Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult
• Differentiation of PTE and Psychogenic Non-Epileptic Seizures (PNES)
• Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality
• Pre-existing conditions including psychological and psychiatric risk factors
• Treatment

Markers and Mechanisms:  Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE, which may include the following:

·         Early detection

• Diagnosis
• Prognosis
• Morbidity
• Comorbidity
• Mortality
• Risk stratification

Note:  Research considering the development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI, could be considered under this Focus Area.

Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

• Seizure frequency and severity
• Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
• Latency between injury and PTE
• Mortality
• Treatment
• Quality of life of individuals with PTE

http://cdmrp.army.mil/funding/erp

Longitudinal Risk Factors Award – Preproposal due July 26, 2018

The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Investigators must have a patient cohort identified.

Intent:  To facilitate high-impact, systematic, cohort-based research investigating the natural evolution of PTE from TBI.

·         Responsive to the Longitudinal Focus Area Only.

·         Preliminary data are required.

·         Must describe how the inter-relationship between TBI and PTE will be assessed or characterized.

·         Must describe the nature of the cohort (military, etc.)

·         Must describe the study outcomes to be captured.

·         Must describe the nature of the TBIs within the study cohort.

·         Requires a Biostatistician.

·         Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.

·         Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

• Maximum funding of $2,500,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

·         Indirect costs may be proposed in accordance with the institution's rate agreement.

Idea Development Award –Letter of Intent due September 20, 2018

Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent:  To solicit research to understand the magnitude and underlying mechanisms of PTE, especially in Service members and Veterans, while also benefitting the civilian community. 

·       Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

·       Level II is intended to support a more mature, hypothesis-driven research project.

The following Focus Areas are open to both Levels I and II:

·         Epidemiology

·         Markers and Mechanisms

·         Longitudinal Studies

·         Preliminary data, while not required, are encouraged for both levels.

Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

Level I:

·       Maximum funding of $300,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 2 years.

·       Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

·       Maximum funding of $500,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 3 years.

Indirect costs may be proposed in accordance with the institution's rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

The FY18 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to explore the causative links between traumatic brain injury (TBI) and epilepsy, with the hope that, one day, post-traumatic epilepsy (PTE) will be preventable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY18 ERP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications should also address at least one of the ERP FY18 Focus Areas.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

The ERP FY18 Focus Areas are as follows:

Epidemiology:  Epidemiological characterization of PTE following TBI, which may include:

• Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult
• Differentiation of PTE and Psychogenic Non-Epileptic Seizures (PNES)
• Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality
• Pre-existing conditions including psychological and psychiatric risk factors
• Treatment

Markers and Mechanisms:  Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE, which may include the following:

·         Early detection

• Diagnosis
• Prognosis
• Morbidity
• Comorbidity
• Mortality
• Risk stratification

Note:  Research considering the development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI, could be considered under this Focus Area.

Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

• Seizure frequency and severity
• Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
• Latency between injury and PTE
• Mortality
• Treatment
• Quality of life of individuals with PTE

http://cdmrp.army.mil/funding/erp

Longitudinal Risk Factors Award – Preproposal due July 26, 2018

The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Investigators must have a patient cohort identified.

Intent:  To facilitate high-impact, systematic, cohort-based research investigating the natural evolution of PTE from TBI.

·         Responsive to the Longitudinal Focus Area Only.

·         Preliminary data are required.

·         Must describe how the inter-relationship between TBI and PTE will be assessed or characterized.

·         Must describe the nature of the cohort (military, etc.)

·         Must describe the study outcomes to be captured.

·         Must describe the nature of the TBIs within the study cohort.

·         Requires a Biostatistician.

·         Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.

·         Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

• Maximum funding of $2,500,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

·         Indirect costs may be proposed in accordance with the institution's rate agreement.

Idea Development Award –Letter of Intent due September 20, 2018

Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent:  To solicit research to understand the magnitude and underlying mechanisms of PTE, especially in Service members and Veterans, while also benefitting the civilian community. 

·       Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

·       Level II is intended to support a more mature, hypothesis-driven research project.

The following Focus Areas are open to both Levels I and II:

·         Epidemiology

·         Markers and Mechanisms

·         Longitudinal Studies

·         Preliminary data, while not required, are encouraged for both levels.

Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

Level I:

·       Maximum funding of $300,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 2 years.

·       Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

·       Maximum funding of $500,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 3 years.

Indirect costs may be proposed in accordance with the institution's rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

Idea Development Award – Letter of Intent due September 5, 2018

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

Early Career Investigators:

Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

·       Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·       Preliminary data are required.

·       Innovation and Impact are the most important review criteria.

·       Clinical trials are not allowed.

·       FY18 KCRP Areas of Emphasis are strongly encouraged.

·       Maximum funding of $400,000 in direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Period of performance is not to exceed 2 years.

Physicians Research Award – Letter of Intent due September 5, 2018

The PI must be a physician with clinical duties and/or responsibilities who, at the application submission deadline, is within 3 years of having initiated his/her first appointment as an Instructor, Assistant Professor, or equivalent

·       Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research.

·       This award emphasizes equally the quality of the proposed research project and the career development of the Principal Investigator (PI), which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.

·       Clinical trials are not allowed.

·       Preliminary data are not required.

·       Maximum funding of $200,000 in direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Period of performance is not to exceed 2 years.

Technology Development Award – Letter of Intent due September 5, 2018

Investigators at or above the level of Assistant Professor (or equivalent) are eligible.

Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems.

·       Supports emerging technologies to aid clinical and patient outcomes.

·       Product-driven award intended to advance the development of technologies to aid clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life.

·       Transition plan is required.

·       Clinical trials are not allowed.

·       Preliminary data are required (need not be in kidney cancer).

·       Maximum funding of $300,000 in direct costs (plus indirect costs).

·       Period of performance is not to exceed 3 years.

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Translational Research Partnership – Letter of Intent due September 5, 2018

The Initiating PI must be at or above the level of Assistant Professor (or equivalent).

The Partnering PI must be at or above the level of Assistant Professor or equivalent.  Postdoctoral fellows are not eligible to be Partnering PI’s.

·       Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

·       Supports translational correlative studies.

·       Preliminary data are required.

·       Clinical trials are not allowed.

·       Maximum funding of $600,000 for direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support the United States Medical Research Acquisition Activity.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

http://cdmrp.army.mil/funding/kcrp

Concept Award – Letter of Intent due July 11, 2018

Investigators at all academic levels.

·       Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

·       Emphasis on innovation.

·       Funding for clinical trials is not allowed.

·       Preliminary data are not allowed.

·       Blinded review

·      Maximum funding of $75,000 for direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Maximum period of performance is 1 year.

he FY18 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY18 LRP must address at least one of the three Focus Areas listed below:

•           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

•           Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.

•           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

http://cdmrp.army.mil/funding/lrp

Concept Award – Letter of Intent due October 10, 2018

Investigators at all academic levels

·         Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

·         Emphasis is on innovation

·         Clinical trials are not allowed

• Preliminary data is not required

·         Maximum funding of $150,000 for total costs

• Maximum period of performance is 1 year

Impact Award – Letter of Intent due October 10, 2018

Investigators at or above Assistant Professor (or equivalent)

·         Supports innovative, high-risk/high-reward research

·         Emphasis is on impact

·         Clinical trials are not allowed

• Preliminary data is encouraged but not required

·         Maximum funding of $525,000 for total costs

• Maximum period of performance is 3 years

A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

A Wenner-Gren grantee may apply for the Engaged Anthropology Grant ($5,000 maximum) upon completion of the final reporting requirements for the Dissertation Fieldwork or Post-Ph.D. Research Grant.

This grant is designed to enable grantees to return to their research locale to share their research results with:

• The community  in which the research was conducted, and/or
• The academic/anthropological community in the region or country of research.

Post-Ph.D. Research Grants are awarded to individuals holding a Ph.D. or equivalent degree to support individual research projects. The program contributes to the Foundation's overall mission to support basic research in anthropology and to ensure that the discipline continues to be a source of vibrant and significant work that furthers our understanding of humanity's cultural and biological origins, development, and variation. The Foundation supports research that demonstrates a clear link to anthropological theory and debates, and promises to make a solid contribution to advancing these ideas. There is no preference for any methodology, research location, or subfield. The Foundation particularly welcomes proposals that employ a comparative perspective, can generate innovative approaches or ideas, and/or integrate two or more subfields.

Dissertation Fieldwork Grants are awarded to aid doctoral or thesis research. The program contributes to the Foundation's overall mission to support basic research in anthropology and to ensure that the discipline continues to be a source of vibrant and significant work that furthers our understanding of humanity's cultural and biological origins, development, and variation. The Foundation supports research that demonstrates a clear link to anthropological theory and debates, and promises to make a solid contribution to advancing these ideas. There is no preference for any methodology, research location, or subfield. The Foundation particularly welcomes proposals that employ a comparative perspective, can generate innovative approaches or ideas, and/or integrate two or more subfields.

The DND Supplement provides additional resources to researchers whose Discovery Grant applications were successful in the Discovery Grants competition and whose research addresses the DND target areas.

Each award is valued at up to $120,000 over three years (up to $40,000 annually). These funds may be used to expand the recipient’s research group (e.g., students, postdoctoral fellows, technicians), to purchase or access specialized equipment, or for other initiatives or resources that would accelerate the recipient’s research program in the targeted areas.